Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of myocardial infarction, stroke, and similar cardiovascular events, but questions remain about the mechanisms behind the cardioprotection the drugs provide. During a virtual symposium Monday morning, Daniel J. Drucker, MD, and two other researchers will address the question, How Do GLP-1 Receptor Agonists Provide Cardioprotection?
Starting soon: How Do GLP-1 Receptor Agonists Provide Cardioprotection?
